Category Image

Global Bladder Cancer Treatment Market Research Report: Forecast (2022-2027)

By Diagnosis (Cystoscopy, Urine Tests, Imaging, Biopsy), By Cancer Type (Urothelial Carcinoma, Squamous Cell, Carcinoma, Adenocarcinoma), By Treatment (Surgery, Chemotherapy (Cisplatin, Gemcitabine, F Read more

  • Healthcare
  • Jun 2022
  • 189
  • HC22085

Market Definition

Bladder cancer is when the DNA in the bladder cells mutates and disables the cell growth functions. In many cases, these mutated cells either die or get attacked by the immune system. However, sometimes they might evade the immune system, multiply aggressively, and form a tumor in the bladder. So far, smoking is the most important risk factor for bladder cancer as tobacco has carcinogenic chemicals that pass into the bloodstream, and kidneys filter them into the urine.

Market Insights

The Global Bladder Cancer Market is projected to grow at a CAGR of around 4.6% during the forecast period, i.e., 2022-27. The growth of the market is driven primarily by the rapidly increasing instances of bladder cancer worldwide, coupled with the escalating focus of governments of different countries on developing robust medical infrastructure & increasing the overall healthcare expenditure.

Report Coverage Details
Study Period Historical Data: 2017-20
Base Year: 2021
Forecast Period: 2022-27
CAGR (2022-27) 4.6%
Regions Covered North America: The US, Canada, Mexico
Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe
Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific
South America: Brazil, Rest of Latin America
Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa
Key Companies Profiled

AstraZeneca PLC, Bristol Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Novartis International AG, Pfizer Inc., Sanofi, Others

Unit Denominations USD Million/Billion

 

Besides, massive R&D investments by the leading biotech & pharma companies in bringing advancements in the current diagnoses & treatments of bladder cancer and offering better success rates & effectiveness on patients are also driving the global market.

Governments across different countries are actively spreading awareness campaigns, advertisements, etc., among people about bladder cancer & the availability of effective therapies to cure the illness. In addition, with the rising geriatric population and higher possibilities of bladder cancer in those above 50 years, there are improved screening rates worldwide as a precautionary step, which projects lucrative prospects for the Global Bladder Cancer Market through 2027.

Impact of Covid-19 on the Global Bladder Cancer Market

In 2020, the Covid-19 pandemic introduced a paradigm shift in the functioning of different industries throughout the world & put immense pressure on the entire healthcare sector. The Bladder Cancer Market witnessed numerous unprecedented challenges associated with its global expansion, principally due to shifting priorities of the healthcare sector to address only Covid-19 patients.

As the effect of the Covid-19 virus was severe, governments of different countries imposed lockdowns & stringent movement restrictions to curb the spread of this dreadful disease. Consequently, such limitations restricted movements of all types and restrained non-critical patients from frequent hospital visits.

However, critical cases were addressed by doctors at hospitals while abiding by the safety norms. With digital transformations, healthcare professionals assisted their non-critical patients remotely using online platforms by exchanging reports & prescribing medications, parceling medications, & scheduling tests.

The most prominent challenges for the bladder cancer market during the pandemic were the halt in research operations and the unavailability of funds. Since governments of different countries invested massively in R&D for developing Covid-19 vaccines & cures, drug discoveries & developments associated with bladder cancer got temporarily suspended. Consequently, the leading players in the Global Bladder Cancer Market witnessed a downfall in revenue generation amidst the crisis.

Global Bladder Cancer Treatment Market Research Report: Forecast (2022-2027)

Market Segmentation

Based on the Treatment:

  • Surgery
  • Chemotherapy
    • Cisplatin
    • Gemcitabine
    • Fluorouracil (5-FU)
    • Mitomycin
    • Others (Doxorubicin, etc.)
  • Immunotherapy
    • Atezolizumab (Tecentriq)
    • Avelumab (Bavencio)
    • Nivolumab (Opdivo)
    • Pembrolizumab (Keytruda)
    • Enfortumab Vedotin (Padcev)
    • Sacituzumab Govitecan (Trodelvy)
  • Radiation Therapy
  • Targeted Therapy
    • Erdafitinib (Balversa)

Amongst all treatments, chemotherapy remains the major contributor to the growth of the Global Bladder Cancer Market. Currently, it is the first-line treatment given to bladder cancer patients. The growing awareness among people about the improving effectiveness & success rates of drugs like cisplatin or carboplatin is driving the demand for chemotherapy treatments for bladder cancer patients and, in turn, fueling the overall market growth.

In some cases, chemotherapy is combined with other treatments to enhance its effectiveness and OS (overall success) rates for bladder cancer patients. Depending upon the case, the oncologist might suggest performing chemotherapy to reduce the tumor size and then opt for surgery, while in some cases, the reverse practice is offered. Chemotherapy drugs are delivered to the bladder using a catheter inserted through the urethra. The most prominent types of chemotherapy drugs used in the treatment of bladder cancer include Cisplatin, Mitomycin-C, Gemcitabine (Gemzar), Docetaxel (Taxotere), & Valrubicin (Valstar), among others.

Besides, with the growing awareness among people about the widespread availability of chemotherapy drugs, coupled with the rising cases of bladder cancer in people, the leading players in the market are set to witness remunerative prospects in the years to come.

Based on the Diagnosis:

  • Cystoscopy
  • Urine Tests
  • Imaging
  • Biopsy

Here, cystoscopy is anticipated to dominate the Global Bladder Cancer Market with the largest share through 2027, principally due to its benefits like a clearer observation of the interiors of the bladder & urethra using a hollow tube known as a cystoscope.

Since this diagnosis allows direct visual inspection of the urothelium, healthcare professionals are able to attain a better understanding of the tumor, size, placement, & other information and prescribe the best treatments. Hence, the demand for cystoscopy for bladder cancer diagnosis is elevating rapidly across the world and, in turn, contributing to the overall market growth.

Regional Landscape

Geographically, the Global Bladder Cancer market expands across:

  • North America
  • South America
  • Europe
  • Middle East & Africa
  • Asia-Pacific

Amongst all regions globally, North America is anticipated to dominate the Bladder Cancer Market with the largest share during 2022-27. It attributes to various aspects, including the rapidly growing patient pool for bladder cancer, rigorous R&D activities across the healthcare sector, especially in the field of oncology, massive investments in developing new drugs for cancer treatment, well-established healthcare facilities, and the extensive presence of leading biotech & pharmaceutical companies across the region.

Governments of different countries are actively focusing on enhancing the healthcare infrastructure to cater to the increasing influx of patients and expand medical tourism. As a result, the growing number of hospitals, research centers & institutes, cancer specialty centers, and pharmacies, among others, are instigating the leading players in the regional market to boost their drug development capacities in order to meet the burgeoning requirements across different medical facilities across North America.

Moreover, countries like the US & Canada are the early adopters of technologically advanced healthcare solutions, i.e., enabling the market players to expand their product portfolio by offering new therapeutic drugs & diagnosis equipment. It would help patients procure medications & therapies at ease and, in turn, stimulate the regional market growth through 2027.

Possible Restraint in the Global Bladder Cancer Market

  • High Treatment Cost & Unavailability of Diagnostic Centers across Rural Areas

The high diagnosis & treatment costs are challenging the affordability of many bladder cancer patients across different corners of the world. Besides, there is less awareness among people about these treatments and the unavailability of diagnostic centers, especially across rural areas. These aspects are likely to hamper the fledged growth of the Global Bladder Cancer Market through 2027.

Key Questions Answered in the Market Research Report:

  1. What are the overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares) of the Global Bladder Cancer Market?
  2. What are the region-wise industry size, growth drivers, and challenges?
  3. What are the key innovations, opportunities, current & future trends, and regulations in the Global Bladder Cancer Market?
  4. Who are the key competitors, their key strengths & weaknesses, and how do they perform in the Global Bladder Cancer Market based on the competitive benchmarking matrix?
  5. What are the key results derived from surveys conducted during the Global Bladder Cancer Market study?

Frequently Asked Questions

A. The Global Bladder Cancer Market is projected to grow at a CAGR of around 4.6% during 2022-27.

A. The rising aging population with a higher possibility of bladder cancer entwined with the growing awareness about the availability of effective diagnosis & treatments are the prominent factors projected to drive the Global Bladder Cancer Market through 2027. However, the unavailability of diagnostic centers & healthcare professionals across rural areas might act as a growth restraint for the global market in the coming years.

A. Chemotherapy is anticipated to emerge as an area of remunerative opportunities for the leading players in the Global Bladder Cancer Market over the forecast years.

  1. Introduction
    1. Research Process
    2. Assumption
    3. Market Segmentation
    4. Market Definition
  2. Executive Summary
  3. Global Bladder Cancer Market Trends & Insights
  4. Global Bladder Cancer Market Regulation & Policy, By Country
  5. Global Bladder Cancer Market Dynamics
    1. Growth Drivers
    2. Challenges
    3. Impact Analysis
  6. Global Bladder Cancer Market Hotspot and Opportunities
  7. Global Bladder Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
        1. Cystoscopy
        2. Urine Tests
        3. Imaging
        4. Biopsy
      2. By Cancer Type
        1. Urothelial Carcinoma
        2. Squamous Cell Carcinoma
        3. Adenocarcinoma
      3. By Treatment
        1. Surgery
        2. Chemotherapy
          1. Cisplatin
          2. Gemcitabine
          3. Fluorouracil (5-FU)
          4. Mitomycin
          5. Others (doxorubicin, etc.)
        3. Immunotherapy
          1. Atezolizumab (Tecentriq)
          2. Avelumab (Bavencio)
          3. Nivolumab (Opdivo)
          4. Pembrolizumab (Keytruda)
          5. Enfortumab vedotin (Padcev)
          6. Sacituzumab govitecan (Trodelvy)
        4. Radiation Therapy
        5. Targeted Therapy
          1. Erdafitinib (Balversa)
      4. By End-User
        1. Hospitals
        2. Specialty Cancer Centers
        3. Others (Ambulatory Surgery Centers, etc.)
      5. By Region
        1. North America
        2. South America
        3. Europe
        4. Middle East & Africa
        5. Asia-Pacific
      6. By Company
        1. Competition Characteristics
        2. Revenue Shares
        3. Competitor Placement in MarkNtel Advisor’s Quadrant
  8. North America Bladder Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Cancer Type
      3. By Treatment
      4. By End-User
      5. By Country
        1. The US
        2. Canada
        3. Mexico
  9. South America Bladder Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Cancer Type
      3. By Treatment
      4. By End-User
      5. By Country
        1. Brazil
        2. Rest of Latin America
  10. Europe Bladder Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Cancer Type
      3. By Treatment
      4. By End-User
      5. By Country
        1. The UK
        2. Germany
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
  11. Middle East & Africa Bladder Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Cancer Type
      3. By Treatment
      4. By End-User
      5. By Country
        1. South Africa
        2. GCC
        3. Rest of Middle East & Africa
  12. Asia-Pacific Bladder Cancer Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Diagnosis
      2. By Cancer Type
      3. By Treatment
      4. By End-User
      5. By Country
        1. China
        2. Japan
        3. India
        4. Australia
        5. South East Asia
        6. Rest of Asia-Pacific
  13. Global Bladder Cancer Market Key Strategic Imperatives for Success and Growth
  14. Competitive Outlook
    1. Competition Matrix
      1. By Application Portfolio
      2. Brand Specialization
      3. Target Markets
      4. Target by Applications
      5. Research & Development
      6. Strategic Alliances
      7. Strategic Initiatives
    2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
      1. AstraZeneca PLC
      2. Bristol Myers Squibb
      3. Eli Lilly and Company
      4. F. Hoffmann-La Roche AG
      5. GlaxoSmithKline PLC
      6. Novartis International AG
      7. Pfizer Inc.
      8. Sanofi
      9. Others
  15. Disclaimer
 Bladder Cancer Market Segmentation